![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced an investment and capacity expansion at its facility in Israel. This investment will support customers’ growing demand for cGMP clinical supply of active pharma ingredients (API) and intermediates and is part of an integrated plan to enhance Recipharm’s offering in drug substances services.
The investment will see the implementation of a full GMP chemical unit including a number of brand-new R&D laboratories and technologies. This will allow Recipharm to support customers through their development projects, from early medicinal chemistry into commercialisation, through a single integrated flow. The expansion is expected to be fully operative by the end of 2021.
Bernard Pluta, President Development Services, commented: ”Recipharm is proud to making this investment. It will be unique in Israel, where we have a talented team who excel at bringing customers molecules to life. Complementing our API development and manufacturing facilities in Europe, the investment provides our customers with a reliable value chain of quality APIs; which will ultimately benefit patients.”
Recipharm’s facility in Israel is located south of Tel Aviv in the vicinity of the Weizmann Science Park. The team specializes in medicinal chemistry. The offering includes a wide array of services in chemical synthesis and analysis including some very demanding and novel specialties. The company also offers analytical and pre-clinical services.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
